HALOZYME ANNOUNCES PRECLINICAL, PHARMACOKINETIC DATA FOR CHEMOPHASE

A A

Halozyme Therapeuticshas reported that preclinical and pharmacokinetic data from its Phase I clinical trial support the safety profile of Chemophase, a high-dose formulation of the recombinant human hyaluronidase enzyme, rHuPH20. Chemophase is under investigation for its potential ability to increase the effectiveness of chemotherapy in the treatment of superficial bladder cancer.

Pharmacokinetic data were obtained from the plasma of five bladder cancer patients dosed intravesically with 20,000 units of rHuPH20 along with 40 mg of the commonly used chemotherapy agent mitomycin, or MMC. The observed plasma levels of MMC were less than 1/40th of the levels reported to be predictive of suppression of white blood cell production.